Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Kalpadakis

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Leukemia & Lymphoma|December 5, 2008
Non-gastric extra-nodal marginal zone lymphomas--a single centre experience on 76 patientsChristina Kalpadakis, Gerassimos A Pangalis, Theodoros P Vassilakopoulos, et al.
Biomed Research International|June 3, 2014
Immunohistochemical analysis of IL-6, IL-8/CXCR2 axis,  Tyr p-STAT-3, and SOCS-3 in lymph nodes from patients with chronic lymphocytic leukemia: correlation between microvascular characteristics and prognostic significanceGeorgia Levidou, Sotirios Sachanas, Gerassimos A Pangalis, et al.
The Oncologist|January 25, 2013
Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomyChristina Kalpadakis, Gerassimos A Pangalis, Maria K Angelopoulou, et al.
Blood|December 5, 2013
Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?Aliki Xochelli, Christina Kalpadakis, Anne Gardiner, et al.
Blood Cancer Journal|March 11, 2018
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study GroupEirini Katodritou, Evangelos Terpos, Sossana Delimpasi, et al.
Scientific Reports|February 20, 2016
Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcomeEleftheria Lakiotaki, Georgia Levidou, Maria K Angelopoulou, et al.
Hematological Oncology|October 31, 2022
Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B-cell lymphoma in the rituximab eraTheodoros P Vassilakopoulos, Fotios Panitsas, Zois Mellios, et al.
Hematological Oncology|May 22, 2012
Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without RituximabSotirios G Papageorgiou, Panayiotis Diamantopoulos, Georgia Levidou, et al.
The Oncologist|August 14, 2015
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41)Amie E Jackson, Michael Mian, Christina Kalpadakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep SequencingMarina Parry, Matthew Jj Rose-Zerilli, Viktor Ljungström, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Leukemia & Lymphoma|December 5, 2008
Non-gastric extra-nodal marginal zone lymphomas--a single centre experience on 76 patientsChristina Kalpadakis, Gerassimos A Pangalis, Theodoros P Vassilakopoulos, et al.
Biomed Research International|June 3, 2014
Immunohistochemical analysis of IL-6, IL-8/CXCR2 axis,  Tyr p-STAT-3, and SOCS-3 in lymph nodes from patients with chronic lymphocytic leukemia: correlation between microvascular characteristics and prognostic significanceGeorgia Levidou, Sotirios Sachanas, Gerassimos A Pangalis, et al.
The Oncologist|January 25, 2013
Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomyChristina Kalpadakis, Gerassimos A Pangalis, Maria K Angelopoulou, et al.
Blood|December 5, 2013
Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?Aliki Xochelli, Christina Kalpadakis, Anne Gardiner, et al.
Blood Cancer Journal|March 11, 2018
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study GroupEirini Katodritou, Evangelos Terpos, Sossana Delimpasi, et al.
Scientific Reports|February 20, 2016
Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcomeEleftheria Lakiotaki, Georgia Levidou, Maria K Angelopoulou, et al.
Hematological Oncology|October 31, 2022
Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B-cell lymphoma in the rituximab eraTheodoros P Vassilakopoulos, Fotios Panitsas, Zois Mellios, et al.
Hematological Oncology|May 22, 2012
Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without RituximabSotirios G Papageorgiou, Panayiotis Diamantopoulos, Georgia Levidou, et al.
The Oncologist|August 14, 2015
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41)Amie E Jackson, Michael Mian, Christina Kalpadakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep SequencingMarina Parry, Matthew Jj Rose-Zerilli, Viktor Ljungström, et al.
Pageof 6